Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Accuredit, Adagio, Advanz, Allecra, Amgen, Atyr, Bridgebio, Bristol Myers Squibb, Can-Fite, Captor, Endo, Halberd, Helmholtz , ITM, Journey Medical, Lysogene, N1, Prellis, Radius Health, Sarepta, Vir, Vyne, Zhittya.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alar, Arrowhead, Blade, Cyteir, Glaukos, I-Mab, IMV, Mesoblast, Pfizer, Revolution, Vaxxinity, Zai Lab.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abiomed, Caredx, Castle Biosciences, Electrocore, Glaukos, Pictor.

LONDON – There was a marked increase in the projected return on investment in pharma R&D in 2021, which rose to 7%, the highest level since 2014. That was up from a lowly 2.7% in 2020 and – even worse – 1.8% in 2019, according to the 12th annual report tracking ROI by the consultants Deloitte. But while 7% is a significant improvement, it is still below the projected ROI when the first edition of ‘Measuring the Return from Pharmaceutical Innovation’ was published in 2010, in response to concerns that pharma was spending more and more on R&D while getting less out. At that point, projected ROI was 10.1%.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 2Seventy, Affibody, Amicus, Beyondspring, Bharat Biotech, Bristol Myers Squibb, Curateq, Heat, Iaso, Immix, Immuron, Innovent, Kintara, Lantern, Lokon, Merck, Mynd Life Sciences, Neogene, Neurocrine, Neurorx, Nuravax, Ocugen, Orion, Panavance, Plus, Relief, Revelation, Sana, Targovax, Xenon, Yumanity.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Advaxis, Aldeyra, Amryt, Ascletis, Awakn, Antares, Applied Genetic Technologies, Basilea, Cansino, Myrtelle, Nascent, Pharmamar, Quantum Leap.

The FDA reported a class I recall of the Wirion embolic protection device by Cardiovascular Systems Inc. (CSI), of St. Paul, Minn., due to reports of nine instances of device malfunction. The agency said the filter portion of the device can be difficult to withdraw under some circumstances and thus lead to separation, although the FDA noted that no deaths have been reported in association with the issue despite the risk of embolization. The FDA’s device center also posted a Jan. 11 notification against the use of two tests by Lusys Labs Inc., of San Diego, for the SARS-CoV-2 virus.